194163-91-2

Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-TRANS-4-CYANO-L-PROLINE METHYL ESTER is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups enable the development of new drugs with improved therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, N-BOC-TRANS-4-CYANO-L-PROLINE METHYL ESTER serves as a versatile building block for the creation of complex organic molecules. Its presence of the BOC protecting group allows for selective reactions, while the nitrile and methyl ester groups provide additional sites for further functionalization.
Used in the Production of Biologically Active Molecules:
N-BOC-TRANS-4-CYANO-L-PROLINE METHYL ESTER is utilized in the synthesis of biologically active molecules, such as peptides, proteins, and other bioactive compounds. Its incorporation into these molecules can enhance their biological activity and potential applications in medicine and research.

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 

Downstream Products

• 194163-92-3 (4R)-1-(tert-Butyloxycarbonyl)-4-(aminomethyl)-L-Proline Methyl Ester 
• 212266-76-7 1-(tert-butyl) 2,4-dimethyl (2S,4R)-pyrrolidine-1,2,4-tricarboxylate 
• 273221-94-6 (2S,4R)-4-cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 53386-75-7 methyl (4R)-4-cyano-1-methyl-L-prolinate 

Relevant academic research and scientific papers

Efficient α-helix induction in a linear peptide chain by n-capping with a bridged-tricyclic diproline analogue

Secondary structure induction: The synthetic tricyclic amino acid ProM-5, which is formally created by stereoselective introduction of a vinylidene bridge into a di-proline unit, acts as a powerful scaffold to nucleate α-helix formation in a linear peptide chain. This might be exploited in the development of new proteomimetics for the modulation of protein interactions. Copyright

SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.